InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,221.42
(
-0.02%
)
US TECH 100
17,716.80
(
0.19%
)
Dow Jones
39,431.51
(
-0.21%
)
Brent Oil
83.28
(
0.08%
)
Bitcoin
62,434.75
(
-0.75%
)
Post# of 251813
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

puravida

Send PM Follow Ignore
Followers 36
Posts 1736
Boards Moderated 0
Alias Born 05/13/2011

puravida

Re: None

Tuesday, 12/06/2016 7:50:21 AM

Tuesday, December 06, 2016 7:50:21 AM

Post# of 251813
Ariad @ASH released ponatinib updates just now

~Final report from Phase 1 study of ponatinib includes approximately five-year median follow-up; Major Molecular Response (MMR) rate was 56 percent

~Pooled Phase 1 and PACE analysis of CP-CML patients with T315I shows 83 percent estimated to maintain major cytogenetic response at four years

http://www.nasdaq.com/press-release/ariad-announces-data-presentations-at-american-society-of-hematology-meeting-20161206-00292#ixzz4S3qJBxDH
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up